澳门大阳城集团2138网站(官方VIP认证)-最新app下载安装

Company Overview

Collaborative Innovation

Hua Medicine is an innovative drug development and commercialization company based in Shanghai, China. Hua Medicine focused on developing novel therapies for patients worldwide with unmet medical needs. Based on global resources, Hua Medicine teams up with global high-caliber people to develop breakthrough technologies and products, which contribute a global innovation in diabetes care.

The Hua Medicine's cornerstone product, HuaTangNing (dorzagliatin tablets, HMS5552), targeting the glucose sensor, glucokinase, restores glucose sensitivity in T2D patients and stabilizes the imbalance of blood glucose levels in patients, it has been approved by the National Medical Products Administration (NMPA) of China on September 30th. It can be used alone or in combination with metformin hydrochloride-tolerated T2D patients. For those patients with chronic kidney disease (CKD) and Type 2 diabetes (i.e., diabetes kidney disease), no dose adjustment is required. Hua Medicine will partner with Bayer, a leading global pharmaceutical company, to commercialize HuaTangNing in China, benefiting diabetic patients and their families.

Clinical trials have shown that HuaTangNing can restore blood glucose homeostasis of Type 2 Diabetes (T2D) patients by repairing the impaired glucokinase to repair glucose sensor function. After the SEED study, Hua Medicine continued to explore the potential of dorzagliatin in diabetes remission, the subjects had a 52-week glucose remission rate of 65.2% during the research period.

As glucose sensor, glucokinase plays a central role in the regulation of glucose homeostasis in human. Impaired glucokinase function leads to glucose sensing defect, resulting in abnormal increase in blood glucose levels, disruption of glucose homeostasis and lipid metabolism, leading to diabetes, metabolic syndrome as well as a series of diabetic complications. As a novel allosteric GK activator, dorzagliatin has demonstrated the potential to repair the defective glucokinase function and restore glucose homeostasis. Dorzagliatin holds the potential to become transformative, especially in the management of T2D and diabetic complications which effectively controls the occurrence and development of diabetes and its complications.

Hua Medicine adheres to the tenet of "For Patients, Global Innovation, Effective Medicines" through the integration of global pharmaceutical research and development resources, joint innovation and mutual benefit operation model, achieving the goal of the healthy development of humans.


2011
Establish
70
%
Specialist
100
+
CRC
Focus Us
Copyright © 2023  Hua Medicine (Shanghai) Co., Ltd.    互联网药品信息服务资格证书编号: (沪)-非经营-2022-0079
沪ICP备14036654号-1  beiantubiao.png 沪公网安备 31011502013809号
Search